ANTIPODES PARTNERS Ltd Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

ANTIPODES PARTNERS Ltd acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,078 shares of the biopharmaceutical company’s stock, valued at approximately $121,000.

A number of other large investors also recently bought and sold shares of GILD. Redwood Financial Network Corp increased its holdings in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC grew its stake in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 99 shares in the last quarter. Nicolet Advisory Services LLC raised its holdings in shares of Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 100 shares during the period. Peak Financial Advisors LLC lifted its stake in Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after acquiring an additional 100 shares in the last quarter. Finally, Perkins Coie Trust Co boosted its holdings in Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Finally, Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $111.38.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at $978,880.80. The trade was a 35.92% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,000 shares of company stock worth $7,844,775. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD traded down $0.43 during midday trading on Thursday, reaching $113.13. The stock had a trading volume of 889,740 shares, compared to its average volume of 8,494,432. The firm’s 50 day moving average price is $109.38 and its 200-day moving average price is $105.56. The company has a market capitalization of $140.72 billion, a P/E ratio of 23.84, a P/E/G ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a 52 week low of $72.43 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.32) earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.